Z-Butylidenephthalide polymer wafer implant- Everfront Biotech

Drug Profile

Z-Butylidenephthalide polymer wafer implant- Everfront Biotech

Alternative Names: BP/polymer wafer; Cerebraca wafer; z-BP/polymer wafer

Latest Information Update: 10 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Everfront Biotech
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Axl receptor tyrosine kinase modulators; Immunomodulators; Nuclear receptor subfamily 4 group A member 1 modulators; Telomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Glioma

Most Recent Events

  • 02 Aug 2017 Everfront Biotech has patent pending for an angelica root extract for treating cancer in Hong Kong (Everfront Biotech website, August 2017)
  • 02 Aug 2017 Everfront Biotech has patent protection for an angelica root extract for treating cancer in Taiwan (Everfront Biotech website, August 2017)
  • 02 Aug 2017 Everfront Biotech has two patents protection treatment of temozolomide-resistant human malignant glioma by z-butylidenephthalide, and anticancer formulation of z-butylidenephthalide wafer against human brain tumour in China (Everfront Biotech website, August 2017).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top